Skip to main content
Equibles

SCTX · Scribe Therapeutics, Inc.

Track SCTX — free

Use SCTX with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SCTX.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$17.10 +0.90 (+5.56%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — cleared Sep 2, 2026

The latest filing states the doubt was alleviated.

“Substantial doubt about our ability to continue as a going concern existed as of June 30, 2026 and was alleviated as a result of the completion of our initial public offering and concurrent private placement, which resulted in aggregate net proceeds of approximately $140.7 million.”
View the 10-Q filed Sep 2, 2026
Market Cap
$320.27M
Shares
18.93M
Volume · Nov 4 204.81K Avg daily vol (3M) 375.75K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$16.20 Open$15.71 Day$15.57–16.47 Available close range$15.41–37.25 Avg vol 30d472K Short int1.1M · 5.9% of shares · 2.4d Short vol85% DataJul 2026–Nov 2026 Filing10-Q · Sep 2

The closing range uses available history since Jul 24, 2026; less than a full year is stored.

Latest documents

2026
Sep 2
Quarterly report 10-Q FY2026 Q2, ended Jun 30
Quarterly report for FY2026 Q2 AI summary on its way
Revenue $1.92M ▼ 60.8% Net loss $6.48M Diluted EPS -$2.62
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
-60.8%
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$43.01M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+1.9%
Year over year · more shares
Price change (1Y)
—
Trailing year
Short interest
5.9%
Latest settlement · 2.4 days to cover
View all 122 metrics

Quarterly results

Revenue Net income Net loss
· $4.90M −$9.90M '25 Q2 LATEST ▼60.8% $1.92M −$6.48M '26 Q2

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Limited Sentiment Neutral Fundamentals Limited Quant / Vol Very High
Market backdrop VIX 20.8 · elevated Equity put/call 0.60
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −31%
below
RSI (14) 40
neutral
MACD trend Positive
52-week position 4%
near low
Momentum
relative strength
Limited
Not enough data for a confident read.
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.91% of shares out · ▼ -54.7% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Squeeze score 44
elevated · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Very High
Volatility 131%
annualized · 1-yr
Max drawdown −59%
past year
ATR 14.6%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
2 · 2 · 1
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−31% Bearish
RSI (14)
40 Neutral
MACD trend
Positive Bullish
52-week position
4% Bearish
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Flat
No 13F holder data
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
5.91% of shares out · ▼ -54.7% MoM · 2.4 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
No 13F holder history
Price context
position in its available closing range
Range low $15 Now $16 · 4% Range high $37
vs 50-day avg -31%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

KPI extraction has been attempted, but no publishable series is available from the examined filings. This is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
SCTX
Scribe Therapeutics, Inc.
this stock
$320.27M — — — 5.9%
VRTX
Vertex Pharmaceuticals Inc
 $134.53B +17.1% +46.2% 34.2 1.7%
REGN
Regeneron Pharmaceuticals, Inc.
 $98.29B +26.1% +20.8% 21.0 2.1%
MRNA
Moderna, Inc.
 $91.20B +674.6% +4.3% — 8.2%
CSLLY
Csl Ltd
 $66.49B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Held by Funds
Fund positions
7
View
Short & Settlement
Short Interest Falling
Shares short
1.1M
Days to cover
2.4d
Change
-1.3M sh
View
Short Volume
Short vol %
85%
As of
Nov 3, 2026
Short Total
View
Fails to Deliver
FTD shares
68.0K
Value
$1.6M
As of
Sep 30, 2026
View
Off-Exchange
Off-exchange %
51.7%
Week of
Sep 28, 2026
Off-exch Lit
View
Filings
SEC Filings
Latest
10-Q
Filed
Sep 2, 2026
This year
6
View
Exempt Offerings
Offering
$100.0M
Filed
Apr 2, 2021
View
Earnings & Events
Investor Relations
Latest news
Scribe Therapeutics Reports Secon…
Published
Sep 2, 2026
View

Performance

5D 20D 120D MTD YTD
SCTX +1.5% -0.8% — +5.1% —
SPY -2.0% -3.2% +1.6% -0.2% +10.6%
vs SPY +3.5% +2.4% — +5.2% —
Key facts CIK 1853921 CUSIP 811033109 13F (30d) 4 filings 4 filers Visit website Investor relations